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The female reproductive tract (FRT) includes the oviducts (fallopian tubes), uterus,
cervix and vagina. A layer of columnar epithelium separates the endocervix and
uterus from the outside environment, while the vagina is lined with stratified
squamous epithelium. The mucosa of the FRT is exposed to antigens originating
from microflora, and occasionally from infectious microorganisms. Whether
epithelial cells (ECs) of the FRT take up (sample) the lumen antigens is not known.
To address this question, we examined the uptake of 20–40 nm nanoparticles
(NPs) applied vaginally to mice which were not treated with hormones, epithelial
disruptors, or adjuvants. We found that 20 and 40 nm NPs are quickly internalized
by ECs of the upper FRT and within one hour could be observed in the lymphatic
ducts that drain the FRT, as well as in the ileac lymph nodes (ILNs) and the
mesenteric lymph nodes (MLNs). Chicken ovalbumin (Ova) conjugated to 20 nm
NPs (NP-Ova) when administered vaginally reaches the internal milieu in an
immunologically relevant form; thus vaginal immunization of mice with NP-Ova
induces systemic IgG to Ova antigen. Most importantly, vaginal immunization
primes the intestinal mucosa for secretion of sIgA. Sub-cutaneous (s.c) boosting
immunization with Ova in complete Freund’s adjuvant (CFA) further elevates the
systemic (IgG1 and IgG2c) as well as mucosal (IgG1 and sIgA) antibody titers.
These findings suggest that the modes of antigen uptake at mucosal surfaces and
pathways of antigen transport are more complex than previously appreciated.

Funding: This work was supported by the start up
funds provided to Vjollca Konjufca by Southern
Illinois University. The funder had no role in study
design, data collection and analysis, decision to
publish, or preparation of the manuscript.
Competing Interests: The authors have declared
that no competing interests exist.

PLOS ONE | DOI:10.1371/journal.pone.0114601 December 9, 2014

1 / 18

Vaginal Immunization with Nanoparticles Primes the Intestinal Mucosa

Introduction
The mucosa of the FRT is a major site of entry and transmission of sexually
transmitted pathogens such as Chlamydia, Gonorrhea, human immunodeficiency
virus (HIV), human papillomavirus (HPV), etc.. In the U.S. alone, about 20
million new sexually-transmitted infections (STIs) occur annually, with the
highest rates amongst young people in their reproductive prime (15–30 years of
age) [1]. In spite of research efforts, the development of mucosal vaccines against
STIs has generally been unsuccessful with the lone exception being parenteral
vaccines against human papillomavirus (HPV), which induce high systemic
antibody titers and protect against HPV challenge [2]. IgG and IgA antibodies
secreted at mucosal surfaces protect against toxins, as well as bacteria and viruses
[3, 4, 5]. Both systemic and local IgG antibodies are also important for protection
against HIV, as demonstrated in rhesus macaques, which were protected against a
vaginal challenge with SHIV when HIV-specific IgG antibodies were administered
either systemically or intra-vaginally [6, 7, 8]. IgG antibodies were shown to bind
to and neutralize the virus, thus preventing its entry into the host via the genital
tract. Therefore, the efficacy of a vaccine that targets STIs will in great part depend
on the vaccine’s ability to induce production of antibodies at mucosal surfaces, in
addition to systemic antibodies. While humoral immunity alone protects against
some pathogens, induction of both cell-mediated and humoral immunity locally
via intra-vaginal immunization is necessary for protection against pathogens such
as C. trachomatis, N. gonorrhea, herpes simplex virus (HSV), HIV, etc.
[9, 10, 11, 12]. Unlike the mucosa of the intestinal tract, mucosa of the FRT does
not contain organized lymphoid tissues, such as Peyer’s Patches (PP) or microfold
cells (M cells) that that are important for the uptake of lumen antigens and for
induction of immune responses. In the intestinal mucosa, soluble and particulate
antigens can enter the internal milieu via M cells [13, 14, 15], goblet cell associated
pathways (GAPs) [16, 17], lamina propria dendritic cells [18, 19, 20], and ECs
[17]. Whether ECs of the FRT play a role in the uptake (sampling) of mucosal
antigens is not known. ECs of the FRT are covered with a layer of mucus that
prevents their direct contact with the lumen antigens originating from microflora
or from infectious microorganisms. It is generally thought that the mucosa of the
FRT is a poor site for induction of immune responses and very little is known
about the modes of vaccination that would maximize both local and systemic
immune responses [21]. However, it is known that immunization via this route is
necessary for the induction of a local immune response. Intra-vaginal
immunizations with non-infective vaccine formulations such as soluble antigens
or inactivated poliovirus induce weak local and rarely systemic humoral immune
responses, possibly because they do not reach the immune cells in the sub-mucosa
of the FRT efficiently [22]. Infections with N. gonorrhoeae, C. trachomatis, group B
streptococci, HSV type 2, or HPV, can induce systemic antibodies, but induce
weak local antibody responses [22, 23]. In a Phase I clinical trial, vaginal
immunization with HIV-1 gp140 antigen without an adjuvant failed to induce
sustained systemic or local IgG, IgA, or T cell responses in women [23]. Studies
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conducted in animals and in humans show that intra-vaginal immunizations with
antigens, co-administered with toxin-based adjuvants, (such as cholera toxin B)
can induce immune responses in the FRT [24, 25]. However, safety concerns
associated with toxin-based adjuvants necessitate development of vaccine
formulations and prime-boost vaccination protocols that can induce both local
and systemic immunity without the use of adjuvants. To enhance antigen entry in
the FRT mucosa without the use of adjuvants, in many studies pre-treatment of
animals with progesterone, followed by mechanical or chemical disruption of the
FRT epithelium is commonly practiced. These approaches were used for vaginal
delivery of PLGA NPs [28], virus-like particles (VLP), HPV [12], and quantum
dots (,10 nm) [29]. However, progesterone treatment was shown to affect both
susceptibility to infections and immune responses in vaccinated animals [26, 27].
In addition, the use of epithelial disruptors would interfere with examining
whether ECs of the FRT sample lumen antigens. We have shown that intestinal
ECs can internalize NPs (20-40 nm in diameter), which are then transported to
the mesenteric lymph nodes (MLNs) that drain the intestine [17]. Here, using 20
and 40 nm NPs as a model particulate antigen, we show that NPs administered
vaginally are internalized by the vaginal ECs, as well as ECs of the upper FRT. In
addition, NPs are transported to the ILNs, MLNs, and the serosa of the large
intestine. We show that intra-vaginal immunization of mice with Ova-conjugated
20 nm NPs, in combination with a s.c. boost, induces systemic as well as mucosal
antibodies. In these studies animals were given no progesterone, the epithelium
was not disrupted by any means, and no adjuvants were used, indicating that the
FRT mucosa, much like the mucosa of the small intestine, has mechanisms by
which antigens from the FRT lumen are internalized and transported to the
internal milieu. Our findings have implications for understanding the biology of
the FRT, as well as for development of mucosal vaccines to target STIs.

Materials and Methods
Ethics statement
This study was carried out in strict accordance with the recommendations in the
Guide for the Care and Use of Laboratory Animals of the National Institutes of
Health. The protocol was approved by the Southern Illinois University
Institutional Animal Care and Use Committee (Protocol Number: 13-057).
Animals were housed in centralized AAALAC-accredited research animal facilities,
staffed with trained husbandry, technical, and veterinary personnel.

Animals, model antigens, reagents, and antibodies
For these studies six to eight week-old female C57BL/6 mice (Jackson
Laboratories) were used. Chicken Ova (Sigma) was used as a model protein
antigen. Carboxylate-modified fluorescent polystyrene nanoparticles (20 nm and
40 nm, Invitrogen), were used as a model particulate antigen, as well as Ova
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antigen carriers for immunizations. For immunization experiments 20 nm NPs
were conjugated to Ova and every batch of conjugated NPs was analyzed by dotblot as described previously [17]. Biotinylated rabbit anti-Ova antibodies
(Thermo Scientific) in combination with streptavidin-FITC (eBioscience) were
used to detect Ova antigen and NP-Ova. To highlight the tissue architecture in
tissue cryosections, actin-binding Phalloidin-Alexa350 (Invitrogen) was used.
Tissue staining with biotinylated Lyve-1 (eBioscience) and E-cadherin (BD
Biosciences) antibodies, followed by FITC-conjugated streptavidin (eBioscience)
was done in order to visualize the lymphatics and the FRT epithelium. Some tissue
sections were stained with antibodies specific for CD11c+ DCs (eBioscience). All
antibodies were used at a 1:100 dilution in blocking buffer.

Administration of NP-Ova to the mice
Mice were instilled vaginally with 10–20 ml of 20 nm NP-Ova (20% diluted in
PBS from an original 2% concentrated stock solution) or PBS (control) on days 0,
1, 3, 5, and 7. The total amount of Ova administered vaginally via NPs was 100–
150 mg. For this, mice were anesthetized lightly with isofluorane delivered in a
stream of oxygen. NP-Ova or PBS solution were administered into the vaginal
canal using a 20 ml pipette. After NP-Ova administration, excess NP-Ova solution
was aspirated and the vaginal opening was thoroughly wiped with cotton swabs
soaked in 70% ethanol in order to preclude the per-oral sampling of NPs via
vaginal grooming. In another experiment, anesthetized mice were administered 5–
10 ml of NP-Ova on days 0, 1, and 2. After NP administration and wiping of the
vaginal opening with ethanol-soaked cotton swabs, mice were fitted with
Elizabethan neck collars and placed in separate cages for up to one week after
immunization in order to preclude per-oral sampling of NP-Ova via grooming.
On day 28 after the first vaginal NP-Ova or PBS administration, mice were s.c.
injected with 300 mg Ova in CFA (Sigma).

Analysis of NP uptake in the FRT and their subsequent transport to
other tissues by immunofluorescence microscopy (IFM) and
confocal microscopy
The internalization of NPs in the FRT and their transport to the draining ILNs,
MLNs, and the large intestine was examined by immunofluorescence microscopy
(IFM) and confocal microscopy. For these experiments mice were anesthetized
with isoflurane delivered in a stream of oxygen, then instilled intra-vaginally with
10–20 ml of 20 or 40 nm red fluorescent NPs diluted in PBS (10–20%). For
examining NP uptake in the FRT and transport to the lymph nodes and the large
intestine, mice were kept under light anesthesia for the duration of the
experiments. At different times post NP instillation, mice were euthanized and the
ILNs, MLNs, FRT, and the large intestine were excised and snap-frozen in TissueTekH O.C.T. freezing compound on dry ice. Tissue cryosections (5–7 mm thick)
were fixed in 4% paraformaldehyde (PFA), washed with PBS then incubated with

PLOS ONE | DOI:10.1371/journal.pone.0114601 December 9, 2014

4 / 18

Vaginal Immunization with Nanoparticles Primes the Intestinal Mucosa

blocking buffer (Thermo Scientific) for 10–15 minutes. Tissue sections were then
stained with fluorescently-tagged antibodies and imaged with a Leica DM4000B
fluorescent microscope. Acquired images were analyzed using Volocity software.
Excised MLNs and ILNs from two experiments (conducted as described above)
were imaged with a confocal microscope as described previously [17].

Collection of vaginal washings, fecal pellets, and blood samples
Before vaginal instillation of NP-Ova or PBS, and every week thereafter, vaginal
washings were collected in 100 ml of PBS. In one study, vaginal washes were
collected in 20 ml of PBS over three days. Blood was collected via the tail vein
using a 30 g needle and serum was separated. Fecal pellets were collected from
each mouse and diluted in PBS containing 0.02% sodium azide (Sigma) to a final
concentration of 100 mg dry matter/ml of PBS. Diluted fecal pellets were
homogenized and then centrifuged at 10,0006g for 10 minutes. All collected
samples were stored at 220 ˚C until assayed.

Determination of Ova-specific antibody titers in vaginal washings,
fecal pellets, and serum samples using ELISA assay
For ELISA assays starting sample dilutions were from 1:10 (for fecal extracts and
vaginal washings) to 1:50 and 1:100 for serum samples prior to boosting. After
boosting immunization starting dilutions for serum samples were up to 1:1000.
Flat-bottomed 96-well plates were coated with 100 ml of 50 mg/ml Ova (Sigma)
solution in coating buffer (0.02 M Na2CO3/0.07 M NaHCO3 in H2O, pH 9.6) and
allowed to incubate overnight at 4 ˚C. After the removal of unbound antigen,
plates were blocked for 1 h at 37 ˚C with 200 ml of blocking buffer (0.2% porcine
gelatin (Sigma) in PBS). Plates were then washed with 200 ml/well of PBS with
0.05% Tween-20 (Sigma) and 0.02% sodium azide (Sigma) three times using an
automated plate washer (BioTek, ELx50). After washing, 200 ml of sample (serum,
fecal extract or vaginal washings, diluted in blocking buffer) were added the first
column of wells and then diluted into successive wells of blocking buffer and
allowed to incubate overnight at 4 ˚C. After overnight incubations, plates were
washed three times and 100 ml of alkaline phosphatase-conjugated goat antimouse IgG1, IgG2c, or IgA (Southern Biotech), diluted 1:2000 in blocking buffer,
were added to each well and allowed to incubate for 2 h at room temperature.
Plates were then washed three times, and alkaline phosphatase (AP) activity was
assayed by adding 100 ml of 1 mg/ml AP substrate (Sigma) and incubating for
20 minutes at room temperature, protected from light. The reaction was stopped
with 25 ml of 3 M NaOH, and the absorbance was read at 405 nm using a plate
reader (BioTek, Epoch).

Detection of Ova-specific antibodies by western blot analysis
For this 1 ml of Ova (10 mg/ml) or PBS (control) was spotted onto a 0.2 mm
nylon membrane and allowed to dry. The membrane was washed with
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Tris-buffered solution containing 0.1% Tween 20 (Sigma) (TTBS), blocked with
TTBS containing 5% skim milk (Difco) for 1 h, then incubated with either serum,
fecal extracts, or vaginal washes diluted in PBS (1:100 for sera and 1:50 for
mucosal washes) overnight at 4 ˚C. After 3 washes, the membranes were incubated
with AP-conjugated goat anti-mouse IgG1or IgA for 1 hour, washed with TTBS,
and the immunoreactive dots were detected by the addition of nitroblue
tetrazolium (NBT)-5-bromo-4-chloro-3-indolylphosphate (BCIP) (Sigma). The
reaction was stopped after 2 to 5 min by washing the membranes with deionized
water.

Statistical analysis
Each experiment was repeated at least three times. Antibody titers were expressed
as log10 of the highest sample dilution that yielded an OD405 value twice that of
the negative control. Data were analyzed using ANOVA procedures of SAS
software. Group means were separated using Student’s t-test and were considered
significantly different at P,0.05. Data are expressed as the mean ¡ standard
deviation of the mean.

Results
NPs are internalized by ECs of the upper and lower FRT and reach
the draining ILNs, MLNs, and the large intestine
In initial experiments we examined whether ECs of the FRT can internalize
(sample) NPs administered in the lumen without treatment with progesterone,
EC disruptors, or mucosal adjuvants. We found that NPs (20 and 40 nm) instilled
vaginally can reach the upper FRT (uterus) and are subsequently internalized by
E-cadherin expressing ECs (Fig. 1 A–E). We then examined the dynamics of NP
internalization by uterine ECs. As expected, no red fluorescence was observed in
the lumen or ECs of the control mice (Fig. 2 A–C). Within 1 h of administration,
NPs were observed co-localizing with E-cadherin+ uterine ECs (Fig. 2 D–F),
however a significant amount of NPs remained within the lumen (L) of the uterus
(Fig. 2 E, F, arrow). At later time points (6–12 h) after vaginal administration,
most of the NPs were observed within the ECs, as well as in the sub-epithelial
compartment (Fig. 2 H, I, box, small arrows), while a small fraction of NPs were
seen in the lumen (L) (Fig. 2 G–I, large arrow), indicating a time-dependent NP
internalization. In addition, NPs were also observed within the lamina propria
and uterine serosa (S1 A–C Figure).
NPs were also internalized by the vaginal ECs (Fig. 3 A, B), and could be
observed as bright clumps within the vaginal epithelium (Ve) (Fig. 3 C, D,
arrows). In addition, NPs reached the sub-epithelial compartments and small NP
aggregates were observed in proximity of CD11c+ DCs (Fig. 3 C, circled). Within
1 h of administration, NPs could be seen in the serosa of the FRT tissue sections
and co-localizing with Lyve-1+ lymphatic ducts that drain the FRT (Fig. 3 E–H).
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Fig. 1. Vaginally applied NPs reach the lumen of the uterus and are internalized by uterine ECs. (A)
H&E stained tissue section of a mouse uterus; (B) An IFM image of the uterine tissue section 3 h after intravaginal administration of 20 nm fluorescent NPs (red). (C, D) Two-color and (E) three color higher
magnification IFM image of the uterine epithelium shown in the boxed inset from panel B. (B–E) Tissue
sections were stained with actin-binding phalloidin-Alexa350 (blue) and anti-E-cadherin antibodies (green),
while fluorescent NPs are shown in red. En-endometrium, My-myometrium, L-lumen, G- mucus glands of the
uterus.
doi:10.1371/journal.pone.0114601.g001

In general, the degree of internalization of NPs by the vaginal ECs was more
variable.
NPs also transported to the ILNs that drain the FRT 1 h after administration
and clumps of accumulated NPs were apparent within ILNs by 3–5 h after
administration (Fig. 4 A–G). NPs were found co-localizing with the Lyve-1+
regions of the ILNs, indicating their association with the lymphatic flow (Fig. 4 A,
C, E, G). Interestingly, NPs also reached the MLNs that drain the intestinal tract
within 1 h of their vaginal instillation and were observed within the adipose tissue
surrounding the MLNs (S2A Figure) and within the MLNs (S2B Figure). At later
times after administration, clusters of NPs were observed within the MLN tissue
sections by IFM (S2C Figure). We then examined the tissue sections of the large
intestine collected from mice to which NPs were administered intra-vaginally.
Surprisingly, NPs were observed within the serosa of the large intestine (Fig. 5 A–
C), indicating that there is some mode of transport that allows vaginallyadministered NPs to reach the large intestine.
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Fig. 2. Internalization of 20 nm NPs by uterine ECs at 1 h and 6 h after intra-vaginal administration. (AC) Two- and three-color IFM images of uterine epithelium from a control mouse. (D–F) Two- and three-color
images of the uterine epithelium at 1 h and (G–I) 6 h after intra-vaginal administration of 20 nm NPs. (H, I) NP
clumps on the basolateral side of the epithelium (box, arrows). Tissue sections were stained with actin-binding
phalloidin-Alexa350 (blue) and anti-E-cadherin antibodies (green), while fluorescent NPs are shown in red.
Scale bar525 mm, L-lumen.
doi:10.1371/journal.pone.0114601.g002

Vaginal immunization with Ova-conjugated NPs induces systemic
IgG1 and IgG2c antibody titers, which can be boosted by s.c.
immunization
We next examined whether vaginal immunization with NP-Ova would elicit
humoral immune responses in immunized mice. For this, anesthetized mice were
vaginally immunized with 20 nm NP-Ova (or PBS), then at day 28 after initial
immunization mice were s.c. immunized with Ova in CFA. A few points are
important to emphasize: 1) Mice were instilled with 10–20 ml of NP-Ova; 2) Any
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Fig. 3. NPs instilled vaginally are internalized by vaginal ECs and drain from the FRT via the
lymphatics. (A) A three color IFM image of a vaginal tissue section. (B) An image of the H&E stained vaginal
tissue section. (C) A three-color IFM image of the vaginal tissue section depicting red NPs within the vaginal
epithelium (Ve) (arrows), and in the sub-epithelial compartment (circled) near CD11c+ DCs (green). (D) A twocolor IFM high magnification (630x) image of the vaginal epithelium (blue) harboring internalized NPs (red).
(E) A three color IFM image of a vaginal tissue section showing the NPs (red) draining from the vaginal tissue
via the lymphatics of the FRT (green). (F) A three-color high magnification image of the boxed inset from panel
E showing NPs (red) draining from the FRT. (G, H) Two- and three-color IFM images of lymph ducts draining
from the FRT and carrying NPs (red). (A, C–H) Vaginal tissue sections were stained with actin-binding
phalloidin-Alexa350 (blue), in combination with (A) E-cadherin (green), (C) CD11c (green), and (E, H) Lyve-1
(green) antibodies, while fluorescent NPs are shown in red. (A–E) Ve-vaginal epithelium, L-vaginal lumen.
doi:10.1371/journal.pone.0114601.g003

excess NPs ‘‘leaking’’ from the vaginal tract were aspirated and the opening of the
vaginal tract was carefully wiped with cotton swabs; 3) In every experiment, about
1/3rd of the mice did not develop titers measurable by ELISA, which we termed
‘‘non-responders’’. In the ‘‘responder’’ mice, vaginal immunization with NP-Ova
induced Ova-specific IgG1 and IgG2c antibodies in sera of immunized mice at day
7, 14, and 28 post-immunization (Fig. 6 A, B). At day 7, 7 of 14 mice were
negative for Ova-specific serum IgG1 at 1:50 dilution, however they were positive
for IgG1 when tested by dot blot (not shown), indicating that the Ova-specific
titers were very low. By week 2 and 3, all 14 mice developed significant serum
IgG1 titers. This s.c. immunization with Ova+CFA at day 28 significantly boosted
the IgG1 and IgG2c serum antibody titers (Fig. 6 A, B). No IgG1 or IgG2c was
detected in sera of mice administered PBS vaginally (control mice) at days 7, 14,
and 28 (Fig. 6 A, B). After s.c. immunization with Ova+CFA, control mice
exhibited elevated serum IgG1 titers, which were comparable to the titers of the
vaginally-primed mice by day 42 (Fig. 6 A). However, control mice immunized
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Fig. 4. NPs distributed within an ILN 5 h after intra-vaginal administration. (A) A three-color stitched IFM
image showing an ILN harboring NPs (red). Two- and three-color higher magnification (630x) IFM images of
the top (B, C), middle (D, E) and bottom (F, G) box insets from panel A showing 20 nm NPs (red) within the
ILN. Tissue sections were stained with actin-binding phalloidin-Alexa350 (blue) and Lyve-1 antibodies (green),
while fluorescent NPs are shown in red.
doi:10.1371/journal.pone.0114601.g004

Fig. 5. NPs administered intra-vaginally transport to the serosa of the large intestine. 10–20 ml of NPs
(diluted to 20% in PBS) were administered vaginally to an anesthetized mouse. Mouse was maintained under
light anesthesia for the duration of the experiment (3 h) at which time the mouse was euthanized and the large
intestine was excised and snap-frozen for IFM analysis. (A) A low magnification stitched IFM image of a
section of the large intestine showing 20 nm NPs (red) in the intestinal serosa. (B, C) High magnification
(630x) IFM images of the boxed insets (B, C) from panel A. A tissue section of the large intestine was stained
with actin-binding phalloidin-Alexa350 (blue) and Lyve-1 antibodies (green), while NPs are shown in red.
doi:10.1371/journal.pone.0114601.g005
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Fig. 6. Antibody titers in sera of mice following priming vaginal immunization with 20 nm NP-Ova and s.c. boosting immunization with Ova in CFA.
Mice were immunized vaginally with 20 nm NP-Ova or PBS (control), then s.c. boosted with 300 mg Ova with CFA at day 28 after priming immunization
(arrows). (A) Ova-specific IgG1 and (B) IgG2c antibody titers are expressed as log10 titer values, with the titer being the highest dilution that yielded an OD405
absorbance value two times that of the negative control. Values represent the mean ¡ SD of samples collected from 14 mice per group (3 separate
experiments). Group means were separated using Student’s t-test and declared significantly different at a P,0.05. Asterisks indicate significant differences
between treatment means.
doi:10.1371/journal.pone.0114601.g006

only s.c. had no serum IgG2c titers, indicating that vaginal immunization with
NP-Ova was needed for induction of IgG1 and IgG2c antibody titers (Th1/Th2
immune response).

Vaginal immunization with NP-Ova induces secretion of sIgA in
the intestinal mucosa
In addition to PP, MLNs are also important sites where antibody diversification
via V(D)J somatic hypermutation and class switch recombination occurs [30].
Based on our observation that vaginally-administered NPs were transported to the
MLNs and the large intestine, we hypothesized that this would lead to imprinting
of gut-specific homing of B cells and IgA class switching. At days 7, 14, and 28
post-vaginal immunization no significant sIgA was detected in fecal extracts of
control or NP-Ova immunized mice (Figs. 7 A, 8 B), however s.c. immunization
with Ova+CFA boosted the sIgA titers (Fig. 7 A, 8 B). This finding indicates that
vaginal immunization did prime the intestinal mucosa for secretion of sIgA and
IgG1, which became apparent after s.c. boosting immunization (Fig. 7, 8 B). The
fact that we could not detect sIgA and IgG1 in fecal extracts after priming
immunization is not surprising, since it is very likely that the amount of sIgA in
fecal pellets was too low.

Vaginal immunization with NP-Ova induces secretion of IgG1, but
not sIgA in the vaginal mucosa
We did not find a significant amount of IgG1 in the vaginal washings at days 7, 14,
and 28 (Fig. 8) in spite of presence of serum IgG1 (Fig. 6 A). S.c. immunization
led to a drastic increase in the amount of IgG1 in the vaginal washings of both
vaginally-primed and control mice (Fig. 8 A). However, vaginally-primed mice
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Fig. 7. Antibody titers in fecal extracts of mice vaginally primed with 20 nm NP-Ova (or PBS, control) and s.c. boosted with 300 mg Ova with CFA at
day 28 after priming immunization (arrows). Fecal pellets were collected each week from individual mice and fecal extracts were assayed by ELISA. (A)
Ova-specific sIgA titers in fecal extracts. (B) Ova-specific IgG1 titers in fecal extracts. Antibody titers are expressed as log10 titer values, with the titer being
the highest dilution that yielded an OD405 absorbance value two times that of the negative control. Values represent the mean ¡ SD of samples collected
from 14 mice per group (3 separate experiments). Group means were separated using Student’s t-test and declared significantly different at a P,0.05.
Asterisks indicate significant differences between treatment means.
doi:10.1371/journal.pone.0114601.g007

had significantly higher IgG1 compared to control mice at day 35 and 42 (Fig. 8
A), although the serum IgG1 titers were comparable between these groups after
s.c. boost (Fig. 6 A). Others have shown that IgG is produced by local B cells of
the vaginal mucosa [31], in addition to being secreted from the serum into the
FRT lumen. We did not detect sIgA in vaginal washings at any time point using
ELISA assay (Fig. 8 B).
To preclude the possibility that observed immune responses in ‘‘responders’’
were not due to ingestion of NP-Ova via grooming we conducted an additional
experiment in which mice were intra-vaginally immunized with 5–10 ml of NPOva at days 0, 1, and 2. After each NP-Ova application, the vaginal opening was
cleaned as described above, then mice were fitted with neck cones (Elizabethan

Fig. 8. Antibody titers of mice vaginally-primed with 20 nm NP-Ova or PBS (control) and s.c. boosted with 300 mg Ova with CFA at day 28 after
priming immunization (arrow). (A) IgG1 antibody titers in vaginal washings. Antibody titers are expressed as log10 titer values, with the titer being the
highest dilution that yielded an OD405 absorbance value two times that of the negative control. Values represent the mean ¡ SD of samples collected from
14 mice per group (3 separate experiments). Group means were separated using Student’s t-test and declared significantly different at a P,0.05. Asterisks
indicate significantly differences between treatment means. (B) Serum, intestinal, and FRT antibody titers of mice that were fitted with Elizabethan neck
collars. Values represent the mean ¡ SD of samples collected from 6 mice per group.
doi:10.1371/journal.pone.0114601.g008
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collars) and kept in individual cages for up to one week after vaginal NP
administration in order to prevent grooming. Similar to previous results,
immunized mice exhibited serum IgG1 titers, but no serum IgG2c or mucosal
IgG1 and IgA antibodies at day 28 after intra-vaginal immunization (Fig. 8 B). S.c.
injection with Ova+CFA boosted serum IgG1 and IgG2c, intestinal IgG1and sIgA,
and FRT IgG1 antibodies (Fig. 8 B). However, we failed to detect sIgA in the FRT
washings by ELISA, although washings were collected in 20 ml of PBS (Fig. 8 B).
An important point that needs to be addressed is that in only half of the animals
(3/6) used in this study, serum IgG1 antibody titers were measurable by ELISA (at
a 1:50 dilution) at day 7 and 14 after vaginal priming. However, Ova-specific IgG1
was detected in sera of all 6 mice by day 7 after vaginal immunization by dot blot
analysis (S3 Figure), indicating that there is variability in the amount of NP
internalization and thus the ensuing immune responses among animals. By day 28
all 6 serum IgG1titers could be measured in all 6 mice. Intestinal sIgA was
measurable by ELISA in animals that had high IgG1/IgG2c titers at day 42 (3/6).
However, sIgA was detected in fecal extracts of all 6 animals by western blot
analysis (S3 Figure). sIgA in vaginal washings was detected by western blot
analysis at 1 week after priming (not shown), however unlike the intestinal sIgA,
the vaginal sIgA titers were not boosted after s.c. injection with Ova+CFA.

Discussion
Immunization via the FRT mucosa is the preferable route for induction of local
immune responses which are essential for prevention of STIs and for limiting
disease severity [32, 33, 34]. However, vaginal immunization is challenging for a
number of reasons. The permeability and sloughing of the FRT epithelium is
under hormonal control, thus the uptake and immunogenicity of vaginallyadministered vaccine formulations can vary drastically depending on the estrus
stage of the immunized animals. Not much is known about the mechanisms of
antigen uptake in the FRT and subsequent transport to the deeper lymphoid
tissues. Based on the finding that ECs of the small intestine can internalize 20 and
40 nm NPs [17], we hypothesized that ECs of the FRT could also internalize NPs
and that NPs could be an effective vehicle for antigen transport from the FRT
lumen to the deeper lymphoid tissues. In this work we show that 1) ECs of the
FRT internalize 20 and 40 nm NPs; 2) internalized NPs are transported to ILNs
that drain the FRT, large intestine, and the MLNs that drain the intestinal tract; 3)
model protein antigen Ova conjugated to NPs reaches the lymphoid tissues in an
immunogenic form and induces systemic antibody responses; and 4) vaginal
immunization with NP-Ova primes the intestinal mucosa for secretion of sIgA. In
addition, we demonstrate that s.c. immunization of vaginally-primed mice further
boosts systemic as well as mucosal antibody responses. We took a number of
measures in order to restrain the mice from grooming the vaginal area and to
prevent oral inoculation with NP-Ova. In addition, since a very small amount of
NPs was used for immunizations, it is unlikely that a sufficient amount of NP-Ova
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was sampled per-orally that would explain the induction of sIgA in intestinal
secretions. Moreover, even if some NP-Ova was sampled per-orally in initial
experiments in which restraint collars were not used, most likely the small amount
of Ova present in these NPs would have been degraded by the gastric acidity and
intestinal digestive enzymes before reaching the intestinal lymphoid tissues. In
addition, the humoral immune responses observed in the study in which neck
collars were used to preclude NP-Ova sampling via grooming confirmed the
initial immunization results, including a high degree of variability in the
magnitude of the humoral immune responses, which is not observed when mice
are immunized s.c..
We argue that this variability stems from differences among mice in the amount
of internalized NP-Ova, although quantifying the actual dose (amount) of Ova
antigen that was internalized by the FRT mucosa is not possible. In addition,
quantification of antibodies in mucosal secretions is challenging in part because
antibodies are diluted in the washing buffer or in the fecal material. In spite of
this, we consistently detected sIgA and IgG1in fecal extracts and vaginal washes,
respectively. It is well established that IgG represents a dominant antibody isotype
in the FRT secretions [35, 36] and it is believed that serum IgG passively enters the
FRT by transudation [21], but is also produced locally by mucosal B lymphocytes
[31]. We could not detect IgG1 by ELISA in vaginal washes prior to boosting
immunization, although serum IgG1 titers were quite high. However, after s.c.
boosting immunization, IgG1 titers in vaginal washings of NP-Ova immunized
mice were higher compared to controls, indicating a local production of IgG1.
Interestingly, in all experiments we failed to observe measurable concentrations of
sIgA in the FRT secretions, although Ova-specific sIgA could be detected by
western blot analysis. Unlike intestinal mucosa, FRT mucosa lacks Peyer’s patches
and the expression of pIgR (that transports the sIgA into the FRT lumen) depends
on the hormonal status of the mice, thus overall IgA titers in vaginal washings can
fluctuate. Others have also reported weak and inconsistent sIgA titers in vaginal
washings of mice immunized with virus-like particles [37]. Since uterine and
vaginal ECs can internalize NPs, it is possible that only internalization by ECs of
the upper FRT can lead to priming of local IgA-producing B lymphocytes. In
support of this possibility, we observed that vaginally-applied NPs do not always
reach the upper FRT. Others have also observed weak or no HIV-1-specific IgA
antibodies in humans [38, 39], chimpanzees, and in SIV-infected macaques, while
IgG antibodies were detected in sera and external secretions of all species
[40, 41, 42, 43]. HIV-positive women with high titers of specific IgG antibodies in
sera and cervical secretions exhibited lower genital viral loads compared to
women that had only serum antibodies [44], underscoring the importance of local
IgG in protection against STIs.
Our finding that NPs administered to the FRT travel to the MLNs where
isotype switch can occur, leading to sIgA class switching and subsequent homing
of sIgA-producing B cells in the intestinal mucosa, is in line with the common
mucosal immune system concept set forth by Bienenstock more than 30 years ago
[45]. We also observed that vaginally-administered NPs also reach the large
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intestine, from where they could be transported to the MLNs. In addition, large
intestines contain organized lymphoid tissues similar to Peyer’s patches of the
small intestine (unpublished observations), thus it is conceivable that the priming
of B cells by NPs may occur there. Whether NPs are passively transported to the
large intestine and the MLNs via the lymph, or whether there are other means of
antigen ‘‘shuttling’’ between the FRT and the intestines remains to be determined.
Another noteworthy observation is that mucosal immunization with NPs
induced a Th1/Th2 polarization, while s.c. immunization alone induced mainly
Th2 type immune responses, as shown by analysis of serum IgG1 and IgG2c
antibody titers. Mucosal priming with NP-Ova appears to be necessary for isotype
switching and Th1 polarization, as s.c. immunization with NP-Ova, similarly to
s.c. immunization with Ova+CFA, induces high serum IgG1, but not IgG2c
(unpublished work). Others have also reported stronger Th1/Th2 polarization in
mice that were primed via a mucosal route compared to s.c. primed mice [46].
These finding are very important for developing novel vaccines and prime-boost
immunization strategies for induction of protective immunity against mucosal
pathogens.
Biodegradable NPs have several advantages that make them attractive for
vaccine development. They are internalized efficiently at mucosal surfaces, they
are non-infectious and easy to administer, and thus raise no safety concerns. In
addition, cocktails of NPs conjugated to a variety of protective antigens can be
administered simultaneously for targeting multiple pathogens. NPs used in our
work are not biodegradable. However, in more than 10 long-term studies, we have
observed no mortality and no adverse effects of NP administration on the health
of animals. We are currently investigating the immunogenicity of biodegradable
NPs, which in time will replace the use of polystyrene NPs. This work will be
important for the development of more effective, needle-free, safe, and affordable
mucosal vaccines and therapies. Mucosally-administered vaccines are especially
appealing for mass immunization of populations in developing countries with a
high prevalence of mucosally-acquired pathogens, including HIV.
Understanding the modes of antigen uptake at mucosal surfaces, antigen
transport to the deeper lymphoid tissues, as well as better understanding mucosal
memory T and B cell differentiation will aid in optimizing prime-boost
immunization strategies for the development of effective mucosal vaccines.

Supporting Information
S1 Figure. Vaginally-administered 20 nm NPs reach the serosa of the uterus.
(A) An image of the H&E-stained uterine tissue section. (B) A three-color IFM
image of the uterine tissue section stained with actin-binding phalloidin-Alexa350
(blue), CD11c antibodies (green), while NPs are shown in red. (C) A high
magnification (630x) image of the boxed inset from panel B depicting clumps of
NPs within uterine serosa.
doi:10.1371/journal.pone.0114601.s001 (TIF)
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S2 Figure. Vaginally-administered NPs reach the mesenteric lymph nodes
(MLNs) within 1 h of administration. (A, B) Confocal images of explanted
MLNs 1 h after vaginal NP administration showing NPs (red) within adipose
tissue surrounding the MLNs (A) and within the MLN tissue (B). In confocal
images, red channel shows NPs, while transmitted light detection was used to
visualize the tissue. (C) IFM image of an MLN tissue section harboring NPs
(arrows) at 12 h after vaginal NP administration. Tissue section was stained with
actin-binding phalloidin-Alexa350 (blue) and NPs are shown in red.
doi:10.1371/journal.pone.0114601.s002 (TIF)
S3 Figure. Dot-blot analysis of serum and fecal extracts of mice vaginallyprimed with 20 nm NP-Ova and s.c. boosted with 300 mg Ova with CFA. After
vaginal immunization, mice were fitted with Elizabethan neck collars. 1 week after
priming, serum samples of all 6 mice were analyzed (1–6). IgG1columns: Ova (or
PBS) were spotted onto nylon membranes, which were then incubated with sera.
SIgA column: Nylon membranes with spotted Ova or PBS were blotted with fecal
extracts collected from individual mice at day 42. Membranes were then incubated
with AP-conjugated goat anti-mouse IgG1 or IgA. Immunoreactive dots were
detected by the addition of BCIP. Images were acquired with a digital camera
(IgG1) or at 2.5x using a microscope (for IgA).
doi:10.1371/journal.pone.0114601.s003 (TIF)
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